Abstract:BACKGROUND: Depression is a prevalent nonmotor symptom in Parkinson disease and can greatly reduce the quality of life for patients; the dopamine receptors found in glutamatergic pyramidal cells in the medial prefrontal cortex (mPFC) play a role in regulating local field activity, which in turn affects behavioural and mood disorders. Given research showing that glial cell-derived neurotrophic factor (GDNF) may have an antidepressant effect, we sought to evaluate the impact of exogenous GDNF on depression-like behaviour in mouse models of Parkinson disease.METHODS: We used an established subacute model of Parkinson disease in mice involving intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), followed by brain stereotaxic injection of GDNF into the mPFC region. Subsequently, we assessed depression-like behaviour using the sucrose preference test, forced swimming test and tail suspension test, while also evaluating protein expression in the mPFC.RESULTS: We included 60 mice, divided into 3 groups, including a control group (saline injection), an MPTP plus saline injection group and an MPTP plus GDNF injection group. We found that exogenous GDNF injection into the mPFC led to an increase in dopamine receptor D1 (DRD1) protein levels. We also observed that activating the protein kinase A pathway through DRD1 produced a prolonged antidepressant response. Under GDNF stimulation, the expression of dopamine receptor D2 (DRD2) remained constant, suggesting that the DRD2 signal was ineffective in alleviating depression-like symptoms. Moreover, our investigation involved Golgi staining and Western blot techniques, which found enhanced synaptic plasticity, including increased dendritic branches, dendritic spines and retrograde protection after GDNF treatment in Parkinson disease models.LIMITATIONS: A subtle motor phenotype became evident only toward the conclusion of the behavioural testing period. The study exclusively involved male mice, and no separate control group receiving only GDNF treatment was included in the experimental design.CONCLUSION: Our findings support a positive effect of exogenous GDNF on synaptic plasticity, mediated by DRD1 signalling in the mPFC, which could facilitate depression remission in Parkinson disease.

Alpha-synuclein Fibrils Inhibit Activation of the BDNF/ERK Signaling Loop in the mPFC to Induce Parkinson's Disease-like Alterations with Depression

Inhibition of Abnormal C/EBPβ/α‐Syn Signaling Pathway Through Activation of Nrf2 Ameliorates Parkinson's Disease‐like Pathology

Altered BDNF levels are associated with cognitive impairment in Parkinson's disease patients with depression

Estrogen-related receptor gamma regulates mitochondrial and synaptic genes and modulates vulnerability to synucleinopathy

Cortical Abnormalities in Parkinson's Disease Patients and Relationship to Depression: A Surface-Based Morphometry Study.

Suppression of Abnormal Α-Synuclein Expression by Activation of BDNF Transcription Ameliorates Parkinson's Disease-Like Pathology.

Reviving: restoring depression-like behaviour through glial cell–derived neurotrophic factor treatment in the medial prefrontal cortex

Targeting the postsynaptic scaffolding protein PSD-95 enhances BDNF signaling to mitigate depression-like behaviors in mice

Alterations of BDNF and trkB mRNA Expression in the 6-Hydroxydopamine-Induced Model of Preclinical Stages of Parkinson’s Disease: An Influence of Chronic Pramipexole in Rats

Inhibition of EHMT1/2 rescues synaptic damage and motor impairment in a PD mouse model

Mir-218-5p and Mir-320A-5p As Biomarkers for Brain Disorders: Focus on the Major Depressive Disorder and Parkinson's Disease.

Transcranial direct current stimulation of the prefrontal cortex improves depression-like behaviors in rats with Parkinson's disease

Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease

Angiotensin-(1-7) relieves behavioral defects and α-synuclein expression through NEAT1/miR-153-3p axis in Parkinson's disease

Involvement of Lateral Habenula Α1 Subunit-Containing GABAA Receptor-Mediated Inhibitory Transmission in the Regulation of Depression-Related Behaviors in Experimental Parkinson's Disease

The ERK Pathway: Molecular Mechanisms and Treatment of Depression

Extracellular Signal-Regulated Kinase is Involved in Alpha-Synuclein-induced Mitochondrial Dynamic Disorders by Regulating Dynamin-Like Protein 1

Potential Impact of Hypoxic Astrocytes on the Aggravation of Depressive Symptoms in Parkinson's Disease

Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies

Chronic corticosterone aggravates behavioral and neuronal symptomatology in a mouse model of alpha-synuclein pathology

Reduced Interaction of Aggregated α-Synuclein and VAMP2 by Environmental Enrichment Alleviates Hyperactivity and Anxiety in a Model of Parkinson’s Disease